SoFi shares rise as record revenue, member growth drive strong Q3 results
Director Iwicki Mark T. of Kala Bio Inc (NASDAQ:KALA) sold 154,894 shares of common stock on October 23, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The company, with a market capitalization of $5.62 million, has seen its stock decline nearly 81% year-to-date according to InvestingPro data. The shares were sold at a weighted average price of $0.81, for a total value of $125,464.
The transactions were executed in multiple sales at prices ranging from $0.78 to $0.85. Following the transaction, Iwicki directly owns 103,540 shares, which includes 103,540 unvested restricted stock units.
In other recent news, Kala Bio, Inc. has faced significant challenges with its KPI-012 treatment for persistent corneal epithelial defect (PCED). The company’s Phase 2b clinical trial failed to meet its primary endpoint, with no statistical significance achieved for key secondary efficacy endpoints. As a result, Kala Bio plans to cease development of both KPI-012 and its mesenchymal stem cell secretome platform. Following these developments, Mizuho analysts have expressed expectations of continued weakness in Kala Bio’s stock. Additionally, Kala Bio received a written notice of default from Oxford Finance LLC regarding its Loan and Security Agreement, with a $29.1 million loan declared immediately due. The notice suggests that other events of default under the agreement may also exist. Meanwhile, Kala Bio’s Board of Directors has scheduled the company’s 2025 annual shareholder meeting for December 11, with further details to be disclosed in a forthcoming proxy statement. These recent developments highlight the company’s current financial and operational challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.